Xuefei Li1, Yanbo Yu1, Zhude Tu1. 1. Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard St. Louis, MO, 63110, USA.
Abstract
The remarkable prevalence of pyrazole scaffolds in a versatile array of bioactive molecules ranging from apixaban, an anticoagulant used to treat and prevent blood clots and stroke, to bixafen, a pyrazole-carboxamide fungicide used to control diseases of rapeseed and cereal plants, has encouraged both medicinal and organic chemists to explore new methods in developing pyrazole-containing compounds for different applications. Although numerous synthetic strategies have been developed in the last 10 years, there has not been a comprehensive overview of synthesis and the implication of recent advances for treating neurodegenerative disease. This review first presents the advances in pyrazole scaffold synthesis and their functionalization that have been published during the last decade (2011-2020). We then narrow the focus to the application of these strategies in the development of therapeutics for neurodegenerative diseases, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD).
The remarkable prevalence ofn class="Chemical">pyrazole scaffolds in a versatile array of bioactive molecules ranging from apixaban, an anticoagulant used to treat and prevent blood clots and stroke, to bixafen, a pyrazole-carboxamidefungicide used to control diseases of rapeseed and cereal plants, has encouraged both medicinal and organic chemists to explore new methods in developing pyrazole-containing compounds for different applications. Although numerous synthetic strategies have been developed in the last 10 years, there has not been a comprehensive overview of synthesis and the implication of recent advances for treating neurodegenerative disease. This review first presents the advances in pyrazole scaffold synthesis and their functionalization that have been published during the last decade (2011-2020). We then narrow the focus to the application of these strategies in the development of therapeutics for neurodegenerative diseases, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD).
Authors: Hui Liu; Richard Laforest; Jiwei Gu; Zonghua Luo; Lynne A Jones; Robert J Gropler; Tammie L S Benzinger; Zhude Tu Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal Journal: N Engl J Med Date: 1997-04-24 Impact factor: 91.245
Authors: Jens Wagner; Sergey Ryazanov; Andrei Leonov; Johannes Levin; Song Shi; Felix Schmidt; Catharina Prix; Francisco Pan-Montojo; Uwe Bertsch; Gerda Mitteregger-Kretzschmar; Markus Geissen; Martin Eiden; Fabienne Leidel; Thomas Hirschberger; Andreas A Deeg; Julian J Krauth; Wolfgang Zinth; Paul Tavan; Jens Pilger; Markus Zweckstetter; Tobias Frank; Mathias Bähr; Jochen H Weishaupt; Manfred Uhr; Henning Urlaub; Ulrike Teichmann; Matthias Samwer; Kai Bötzel; Martin Groschup; Hans Kretzschmar; Christian Griesinger; Armin Giese Journal: Acta Neuropathol Date: 2013-04-19 Impact factor: 17.088